Evozyne LLC, a privately held molecular engineering technology company founded by life science company Paragon Biosciences, announced on Monday that it has signed a strategic collaboration and license agreement with Japan-based Takeda Pharmaceutical Company Limited.
According to the contract, Evozyne's evolution-based protein design technology is to be used to research and develop proteins that could be applied to next generation gene therapies for genetic disorders within the inborn errors of metabolism and lysosomal storage disease areas of research. The partnership will result in Evozyne being eligible to receive an upfront payment and additional research, development and regulatory milestone payments; and royalties on sales of any commercial products.
Rama Ranganathan, MD, PhD, co-founder and chief scientific officer of Evozyne, said, 'People living with inborn errors of metabolism diseases have profound deficiencies in enzyme levels or lack of enzyme activity that lead to the build-up of toxic materials in the body. For years, researchers have been working to convert existing cells to express the missing enzyme. We now have the ability to create new enzymes that could enable more effective gene therapy approaches that may have a greater impact on patients with these disorders.'
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study